Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa

US9688645B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Christopher Kallus · Frankfurt am Main, DE
• Mark Broenstrup · Frankfurt am Main, DE
• Andreas Evers · Frankfurt am Main, DE
• Anja Globisch · Monheim am Rhein, DE
• Herman Schreuder · Frankfurt am Main, DE
• Michael Wagner · Frankfurt am Main, DE

Key dates

• Filing date: Mar 1, 2016
• Grant date: Jun 27, 2017
• Expiry date: Mar 1, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.